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Abstract
Background: Septoplasty (surgery to straighten a deviation in the nasal septum) is a frequently performed operation
worldwide, with approximately 250,000 performed annually in the US and 22,000 in the UK. Most septoplasties aim to
improve diurnal and nocturnal nasal obstruction. The evidence base for septoplasty clinical effectiveness is hitherto very
limited.
Aims: To establish, and inform guidance for, the best management strategy for individuals with nasal obstruction
associated with a deviated septum.
Methods/design: A multicentre, mixed-methods, open label, randomised controlled trial of septoplasty versus medical
management for adults with a deviated septum and a reduced nasal airway. Eligible patients will have septal deflection
visible at nasendoscopy and a nasal symptom score≥ 30 on the NOSE questionnaire. Surgical treatment comprises
septoplasty with or without reduction of the inferior nasal turbinate on the anatomically wider side of the nose. Medical
management comprises a nasal saline spray followed by a fluorinated steroid spray daily for six months. The recruitment
target is 378 patients, recruited from up to 17 sites across Scotland, England and Wales. Randomisation will be on a 1:1
basis, stratified by gender and severity (NOSE score). Participants will be followed up for 12months post randomisation.
The primary outcome measure is the total SNOT-22 score at 6months. Clinical and economic outcomes will be modelled
against baseline severity (NOSE scale) to inform clinical decision-making. The study includes a recruitment enhancement
process, and an economic evaluation.
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Discussion: The NAIROS trial will evaluate the clinical effectiveness and cost-effectiveness of septoplasty versus medical
management for adults with a deviated septum and symptoms of nasal blockage. Identifying those individuals most likely
to benefit from surgery should enable more efficient and effective clinical decision-making, and avoid unnecessary
operations where there is low likelihood of patient benefit.
Trial registration: EudraCT: 2017–000893-12, ISRCTN: 16168569. Registered on 24 March 2017.
Keywords: Nasal septum, Nasal obstruction, Septoplasty, Turbinates, Mometasone furoate, Clinical trial, Cost-effectiveness,
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Background
Septoplasty is surgery to straighten the nasal partition be-
tween the two nostrils (the septum). Septoplasty is a com-
monly conducted operation worldwide, with approximately
250,000 operations performed annually in the US and ap-
proximately 22,000 in the United Kingdom (UK) [1, 2].
Most of these are carried out for nasal blockage and associ-
ated symptoms such as a snoring and sleep disturbance.
Nasal blockage is one of the commonest complaints pre-
senting to otolaryngologists. However, the causes may be
multiple, and several may be co-existent. Septal deviation
or lesions in the nasal passages, such as nasal polyps or en-
larged adenoids or turbinates, may cause a ‘fixed’ sensation
of blockage. ‘Fluctuating’ blockage symptoms may be
caused by inflammatory conditions of the nasal epithelium
such as infective or allergic rhinitis. In addition, the ‘nasal
cycle’, a spontaneous physiological congestion and decon-
gestion of the nasal cavity, compounds the challenge in
characterising and assessing nasal patency [3]. The impact
of the ‘nasal cycle’ can be mitigated by measuring nasal air-
flow following therapeutic nasal decongestion [3].
Ideally, the septum runs down the centre of the nose. If it
is not straight, perhaps because of injury or a developmen-
tal anomaly, it may narrow one or both sides of the nose
and obstruct airflow. A perfectly straight nasal septum in
adults is rare and some degree of deviation is an accepted
norm. However, in instances where there are symptoms of
nasal obstruction and a concomitant deviation of the
septum, patients may be offered the septoplasty operation.
On the sidewalls of the nose are ‘turbinates’, tissue
structures which are rich in blood vessels and glands.
Often when the septum narrows one side of the nose, it
creates a larger space on the other side, into which the
turbinate on that side expands. Medical management
using topical nasal steroid sprays decongests the nasal
lining and may lead to improvement in the symptoms of
nasal blockage. However, such treatments are required
on a daily, ongoing basis and in practice may not be suc-
cessful. In addition, side effects of nasal dryness, irrita-
tion and bleeding may impact on treatment satisfaction
and compliance. When surgery to straighten the septum
is carried out, some surgeons also reduce the contralateral
turbinate tissue. Potential complications of septoplasty
include septal perforation, septal adhesions and bleeding
[4]. Post-operative pain is common although this is re-
duced if sutures rather than nasal packing are used [4–6].
Patients typically are advised to take several days off work
or usual activities after the operation. Septoplasty has no
defined selection criteria, particularly in patients whose
principal symptoms are sleep related, and clinical practice
varies in different centres. The mode of action of septo-
plasty in sleep-related breathing disorders is not fully
understood [7–9].
The effectiveness of septoplasty with or without turbinate
surgery remains unclear and there is a lack of high-quality
evidence of its benefit in the literature [10, 11]. Not all pa-
tients improve with surgery. Estimates of persistent septal
deviation following a septoplasty procedure range from less
than 6% [12] to 20% [13]. Where septoplasty fails and fur-
ther surgery becomes necessary, revision rates are reported
to be high [14]. There is also a lack of robust evidence
about the additional benefit of turbinate surgery [11]. One
study showed reduced revision rates for septoplasty when
the turbinate tissue is reduced [15]; other studies report no
added long-term benefit from turbinate reduction [16–18].
Currently, most septal surgery is based on subjective,
unstandardised clinical impressions of the contribution
of the nasal septum to patients’ symptoms. There is also
no good comparative evidence regarding alternatives to
septal surgery; nor about who might most benefit, to in-
form patients’ and doctors’ shared surgical decision-
making [11].
Whilst it is recognised that that the evidence base for
septoplasty is ambiguous [11], it is important to take
into account the variations between men and women in
relation to the operation. Firstly, septoplasty is more
common in men [4, 11] and, secondly, there is a known
gender influence on response to nasal-patient reported
outcome measures [1].
The aim of NAIROS is to establish, and inform guid-
ance for, the best management strategy for patients
with nasal obstruction associated with a deviated nasal
septum, via a randomised controlled trial (RCT) of sur-
gery versus medical management across 17 sites in both
secondary and tertiary hospitals across England,
Scotland and Wales.




To establish, and inform guidance for, the best manage-
ment strategy for participants with nasal obstruction as-
sociated with a deviated septum, via a randomised
controlled trial comparing the clinical and cost-
effectiveness, of nasal septoplasty plus/minus (±) contra-
lateral turbinate reduction versus medical management.
Objectives
The study objectives are split into three different aspects:
clinical effectiveness, economic evaluations and mixed-
method process evaluation.
Clinical effectiveness To measure clinical effectiveness
according to:
 Subjective self-report rating of nasal airway
obstruction
 Heterogeneity of estimated treatment effect
specifically according to severity of obstruction and
gender
 Objective measures of nasal patency
 Number of adverse events (AEs) and additional
interventions required
 Technical failure in the surgical arm
 How well those agreeing to enter the trial reflect
those screened for eligibility
Economic evaluation
 The cost-effectiveness of each intervention
 The cost-utility with outcomes reported as incre-
mental cost per Quality Adjusted Life Year (QALY)
gained
 A longer-term economic model to assess costs and
health consequences beyond 12-month follow-up
period
 All economic analyses will be conducted from the
perspective of the National Health Service (NHS)
and participants
Mixed-methods process evaluation of the trial and
interventions Our mixed-method process evaluation
will identify, describe, understand and address:
 Barriers to optimal recruitment, and potential
solutions to address these, through integration of the
QuinteT Recruitment Intervention (QRI) [19, 20]
 Participants’ and healthcare professionals’
experiences of trial participation and the
interventions under evaluation
 Factors likely to influence wider implementation of
trial findings
The design, measured outcomes and analysis of the
process evaluation and QRI are detailed later in this
manuscript.
Trial design and duration
A multicentre, randomised controlled, open-label trial, in-
corporating a qualitative process and economic evaluation.
Participants will be randomised on a 1:1 basis between
septoplasty, with or without turbinate reduction, versus
medical management (Isotonic Saline Nasal Spray (Steri-
mar) and Mometasone Nasal Spray) of nasal obstruction.
Participants in the medical management arm will be asked
to use the nasal sprays twice daily for 6 weeks, then once
daily for the remainder of the 6-month period. Recruit-
ment will take place over 20months, with trial completion
complete at 42months (submission of final report).
Trial setting
The trial will take place in 17 NHS hospitals across
Scotland, England and Wales (see the ISRCTN registry
number 16168569). An overview of the NAIROS sched-
ule of events patient pathway is shown in Fig. 1.
Target population
Adults (aged ≥ 18 years) referred by their general practi-
tioner (GP) to Ear, Nose and Throat (ENT) secondary
care outpatient clinics who are found to have a deviated
septum on nasendoscopy and reduced nasal airway as
indicated by a NOSE score ≥ 30. ENT staff will also be
recruited for participation in a process evaluation.
The NAIROS eligibility criteria are listed in Table 1.
Participant identification, consent, screening and
randomisation
Hospital researchers will proactively identify NAIROS-
eligible patients through triage of referral letters of rhi-
nology patients to the ENT department, and issue an in-
vitation to attend a research clinic. Patients attending a
research clinic will, where possible, have been sent the
Patient Information Sheet (PIS) with their appointment
details, and have been directed to the Patient Informa-
tion Video, available at www.NAIROS.co.uk. All patients
will have been given a minimum of 24 h after receiving
the PIS to decide whether or not they would like to take
part. The main PIS can be found in Additional file 1.
Consent A delegated member of the research team will
undertake informed consent discussions with the oppor-
tunity for the patient to ask any questions and discuss
the trial in more detail. Patients will be invited to give
informed, written consent in three stages. Firstly, con-
sent to undergo screening (eligibility). Secondly, consent
to have the discussion about the NAIROS trial with the
investigator audio-recorded and their details passed onto
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Fig. 1 Flow Diagram of the Nasal Airway Obstruction Study (NAIROS) schedule of events
Table 1 Nasal Airway Obstruction Study (NAIROS) eligibility criteria
Inclusion criteria Exclusion criteria
• Adults aged ≥ 18 years
• Baseline NOSE score≥ 30
• Septal deflection at baseline visible via nasendoscopy
• Capacity and willingness to provide written informed
consent and complete the trial questionnaires
• Any prior septal surgery
• Systemic inflammatory disease or the use of any current oral steroid
treatment within the past 2 weeks
• Granulomatosis with polyangiitis
• Nasendoscopic evidence of unrelated associated pathology, e.g. adenoid pad, septal
perforation, chronic rhinosinusitis indicated by the presence of polyposis or pus
• Any history of intranasal recreational drug use within the past 6 months
• Breast-feeding, pregnancy or intended pregnancy for the duration of involvement in
the trial
• Bleeding diathesis
• Therapeutic anticoagulation (warfarin/novel oral anti-coagulant (NOAC) therapy)
• Clinically significant contraindication to general anaesthesia
• Patients known to be immuno-compromised
• Those in whom an external bony deformity substantially contributes to the nasal
obstruction
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a member of the qualitative team for a telephone inter-
view. Finally, eligible patients are invited to give consent
for the main trial, and to also give consent to potential fu-
ture sharing of their anonymised data with other re-
searchers not related to the NAIROS study. The patient
Informed Consent Form can be found in Additional file 2.
Screening Screening data used to assess eligibility will
include:
 Clinical examination (including nasal endoscopy)
 Nasal Obstruction Symptom Evaluation Scale
(NOSE) score – confirmation of total ≥ 30
 Age
 Baseline recording of four core features at
endoscopy of the undecongested nose
◦ The side of the maximum convexity
◦ One main site of deflection on each side –
anterior/ posterior/upper/lower/all)
◦ Confirmation that there is no excluding
inflammatory process – pus/polyps/adenoids
◦ Magnitude of observer-rated airway block (<
50%; ≥ 50%)
If the participant is unable to complete the endoscopic
examination without topical preparation, it can be per-
formed after the airway assessment of the decongested
nose.
The NOSE scale is a validated five-item, unifactorial
self-report of nasal-block severity which has been applied
in previous research and audit studies [21, 22]. The three
recognised NOSE-derived categories of baseline severity
used will be: 30–50 =Moderate, 55–75 = Severe, 80–
100 = Extreme [22].
For NAIROS, it is anticipated that baseline severity
will be the most important determinant of outcome.
Those with a NOSE score of less than 30 will be ex-
cluded from NAIROS on the basis of having symptoms
that are too mild to warrant inclusion.
Randomisation At the baseline visit, consenting, eligible
patients will be randomised on a 1:1 basis using random
permuted blocks of variable length. Stratification will be
by gender and baseline severity (NOSE score).
Randomisation will be administered centrally by the
Newcastle Clinical Trials Unit (NCTU) web-based system.
The treatment allocation is open label and the randomisa-
tion system will provide a unique trial identifier for each
participant via email to a delegated member of site staff.
Participants will be randomised between:




Participants allocated to the septoplasty group will
undergo surgical correction of the nasal septal deviation ±
unilateral reduction of the inferior turbinate on the con-
cave side. A preliminary secondary care feasibility exercise
revealed that there is considerable variation in surgical
practice around the UK; rates of contralateral turbinate re-
duction varied between NAIROS centres from 30 to 65%
of septoplasties. As a pragmatic study, NAIROS does not
ask surgeons to change their usual practice in relation to
contralateral turbinate reduction. NAIROS surgeons may
or may not carry out unilateral turbinate surgery on the
wider side, according to their assessment of the individual
patient airway. Intention to reduce one turbinate will be
recorded prior to randomisation. Details of the actual sur-
gery performed will also be collected.
Participants will have a closed septoplasty, will be su-
tured, not packed, and will be a day case (where pos-
sible). The recommended post-operative twice-daily
regimen will be of saline douche plus Naseptin Nasal
Cream (or if the patient is allergic to the peanut content
of Naseptin, Bactroban 2% ointment). Participants will
be recommended to take a few days off work.
Nasal-steroid and saline sprays should not be part of
routine standard post-operative care for NAIROS. Any
additional medication required by participants will be re-
corded as concomitant medication.
Surgery must be carried out anytime up to 8 weeks (+ 4
weeks) after randomisation. The additional 4-week win-
dow is to allow for extenuating circumstances only, such
as unexpected patient or clinical reasons that necessitate a
delay in surgery. Reasons for delays to surgery will be col-
lected and reported. The surgical intervention will be per-
formed by surgeons who have completed their training.
Intervention – medical management
Patients randomised to the medical management arm
will be asked to use a combination of an isotonic spray
with a full twice-daily dose of a fluorinated steroid spray
(mometasone furoate) which is a typical maximal med-
ical therapy regime over a 6-month period. Preparatory
work by the chief investigator indicated that most pa-
tients referred from their GP have never used this sus-
tained combination therapy.
Sterimar Isotonic Nasal Spray dose: one spray (metred
dose) into each nostril prior to using the Mometasone
Nasal Spray.
Mometasone Nasal Spray dose: 100 mcg (two sprays)
into each nostril twice daily for 6 weeks, followed by 100
mcg (two sprays) into each nostril once daily or 50 mcg
(one spray) into each nostril twice daily for the remain-
der of the 6-month period.
Participants who wish to discontinue their allocated
treatment, but remain in the trial, may access other
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treatments via the standard local NHS route. Such par-
ticipants will be followed up as per their allocated treat-
ment intervention arm. Participants in the surgical arm
who wish to pursue medical treatment will not receive
the trial Investigational Medicinal Product (IMP) pre-
scription. Participants in the medical arm who wish to
receive surgery and remain eligible for septoplasty
should be added to the elective NHS waiting list.
Primary outcome measure
The primary analysis is comparison of the comprehen-
sive, validated Sino Nasal Outcome Test–22 (SNOT-22)
[23] patient-reported scores at 6 months from random-
isation (− 2 weeks to + 4 weeks), with complete follow-up
of participants to 12 months post randomisation. SNOT-
22 is a commonly employed patient reported outcome
measure in the assessment of patients with pathologies
of the nose and sinuses [23–30] and was first applied to
septoplasty in 2003 [31]. Our PPI work found that pa-
tient symptoms mapped better to the SNOT-22 than to
the NOSE and that patients preferred the SNOT-22
measure. To maximise collection of primary outcome
measure, participants who cannot attend the 6-month
follow-up visit may complete SNOT-22 by post.
Secondary outcome measures
Secondary outcome measures can be categorised into
patient-reported, safety, economic, exploratory and
qualitative.
Patient Reported Outcome Measures (PROMs) PROMs
will be used to measure long-term change in nasal pa-
tency and quality of life:
 SNOT-22 subscales (Rhinologic, Sleep, Ear/facial
pain, Psychological) at 12 months
 NOSE scale at 12 months
 Double Ordinal Airway Subjective Scale (DOASS) –
administered post nasal decongestant use only at 12
months. DOASS is a subjective comparator of right
and left nasal patency [32] allowing direct
comparison with the spirometry measures
Safety outcomes Safety outcomes will be measured by
the number and characteristics of any AEs, and surgical
complication/failure and re-intervention within 12
months.
Economic outcomes Economic outcome measures
include:
 QALY gained using the 36-item Short Form Health
Survey (SF-36) questionnaire (1-week recall), further
converted into QALYs using the Health Economy
Survey derived from SF-36 (SF-6D) algorithm [33],
at 12 months, and AEs avoided
 Use of and timing of additional interventions in
primary and secondary care recorded by Health
Care Utilisation Questionnaire at 6 months and 12
months
 Number of days unable to undertake usual activities
recorded by Health Care Utilisation Questionnaire
at 6 months and at 12 months
 Incremental cost per change in SNOT-22 at 12
months
 Costs to NHS and participants at 12 months
 Longer-term economic model to assess costs and
health consequences beyond the trial
Exploratory outcome measures Two of the most com-
mon objective measures of nasal patency, used in some
overseas healthcare systems to assess likely benefit from
septoplasty, are peak nasal inspiratory flow rate (PNIF)
and nasal partitioning ratio (NPR) [34]. PNIF and NPR
will be used in this trial as exploratory outcome measures.
All sites will be provided with two devices to measure
two different measurements of nasal patency:
 PNIF, measured with a PNIF meter (Peak Nasal
Inspiratory Flow (PNIF) Meter; GM Instruments,
Kilwinning, UK)
 NPR, measured using the NV1 rhinospirometer
(NV1 rhinospirometer; GM Instruments,
Kilwinning, UK)
The two standard measurements will each be made
before and after decongesting the nasal turbinate tissue
with xylometazoline at baseline and at 6 and 12months
following randomisation.
PNIF measures the peak flow rate of air through both
nostrils during inhalation using a PNIF meter with a face
mask. The participant holds the mask over the nose and
mouth, closes the mouth and inhales maximally (sniffs).
PNIF has been shown to respond to septoplasty/turbi-
nectomy [35] and can, therefore, be used for an overall
assessment of nasal airflow impairment, and as an ob-
jective outcome measure from surgery. However, PNIF
does not differentiate between the two nostrils.
Bench testing shows the NV1 rhinospirometer to be
an accurate and precise objective marker of airflow sym-
metry [36]. The NV1 rhinospirometer has two separate
channels to measure the volume of air passing through
each nostril, hence deriving the NPR, the difference be-
tween right and left volumes divided by the sum. NPR
ranges from symmetrical (0) to completely unilateral (±
1). The NPR appears to predict the septal surgery out-
come [34, 37]. Comparison of NPR during both maximal
inhalation and normal tidal breathing will allow the
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comparative utility of these two measures to be com-
pared and demonstrate any change in nasal function fol-
lowing treatment.
Qualitative outcomes Qualitative outcomes will be
identified through observations of training and NAIROS
meetings, interviews with health professionals and partici-
pants, and audio-recording of recruitment discussions.
Data collection
The trial schedule of events is presented as a flow dia-
gram (Fig. 1) and using the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
Figure [38] (Fig. 2). Participants recruited to the main
trial will be followed up for 12 months from the point of
randomisation.
Data including the number of participants screened,
approached and interested in taking part will be col-
lected via a log completed by site staff conducting
screening.
Assessments pre-randomisation Eligible patients who
consent to participate in the main trial will have the follow-
ing outcome measures administered prior to randomisation:
 SF-36 questionnaire (1-week recall version)
 SNOT-22 questionnaire




 Double Ordinal Airway Subjective Scale (DOASS)
Surgical arm data The operating surgeon will record:
 Date of surgery
 Time into and out of theatre and duration of
anaesthetic
 Highest grade of anaesthetist and surgeon
 Whether septoplasty ± unilateral turbinate reduction
was carried out
Fig. 2 Nasal Airway Obstruction Study (NAIROS) schedule of events
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 Technical aspects of the surgical procedure (flap
type, closure, use of mattress sutures to septum, use
of packs/splints)
 Whether there were any complications
 Discharge medication (concomitant medication)
Site nursing staff will record details of any concomitant
medication and AEs during a phone call at 2 weeks after
surgery has taken place, and at all scheduled trial visits.
Medical management arm data As a pragmatic trial
using standard treatment as part of the medical manage-
ment arm, precise assessment of any mometasone furo-
ate spray and Sterimar spray residuum will not take
place. Participant compliance with the IMP does not
form part of the trial monitoring plan. Participants will
be asked at the 6-month follow-up visit (visit 2) to esti-
mate how many bottles of the Sterimar and mometasone
furoate spray they used.
Site nursing staff will record details of concomitant
medication and any AEs during a phone call at 2 weeks
post randomisation and at all scheduled trial visits.
Data handling and record keeping
Data will be handled, computerised, stored and archived
in accordance with the General Data Protection Regula-
tion (2018), and the latest Directive on Good Clinical
Practice (GCP) (2005/28/EC). Patient-identifiable data will
remain at each site and not be collected as part of the trial
dataset. Patient identification on data collection tools used
during screening will be through a unique sequential
screening number allocated by site staff. Patients recruited
to the main trial will additionally be identified by a unique
trial identifier number generated by the randomisation
system. Data will be transcribed and NPR files uploaded
by site staff to the trial’s secure, password-limited, vali-
dated MACRO™ database (Elsevier).
The participant trial record, including completed
paper data collection tools, will be archived at site for 5
years following the end of the trial. Audio-recordings
will be archived for 10 years.
Trial compliance and withdrawal
The trial will be conducted in accordance with the Medi-
cines for Human Use (Clinical Trials) Regulations 2004 and
subsequent amendments. All parties must abide by these
regulations and the International Conference on
Harmonisation-Good Clinical Practice (ICH-GCP)
guidelines.
Participants who withdraw their consent from the trial,
or are withdrawn by the investigator, will not be re-
placed. All data collected up until the point of with-
drawal will be retained for NAIROS research purposes,
and consent will be sought for this (Additional file 2).
Sample size calculations
The SNOT-22 Minimal Clinically Important Difference
(MCID) in the National Comparative Audit of Surgery for
Nasal Polyposis and Chronic Rhinosinusitis was 8.9 [23].
Septal surgery is reported variously as showing reductions
in total SNOT-22 scores above (10 points) [29] or below
(4 points) this boundary [25]. In the absence of a specific
figure for septoplasty MCID, NAIROS has assumed a clin-
ically relevant reduction being at least 9 points.
Reported standard deviations (SD) of the SNOT-22
score were 18 [27] (in external septoplasty) to 24 [28] in
septorhinoplasty, NAIROS assumed the larger, more
conservative SD.
Sample size calculations were based on a t test for super-
iority assuming equal variance across groups, a conservative
estimate given the primary analysis is based on adjustment
for stratification covariates, increasing power. The target re-
cruitment of 378 participants allows for 20% drop-out –
based upon experience from our unit’s two prior septal sur-
gery audits [10, 39]. The remaining 302 participants (151
per arm at completion), are required to show a 9-point [23]
difference in overall SNOT-22 score between arms, with
90% power and 5% Type I error, assuming a SD of 24.
Statistical analyses
Primary outcome The primary analysis is comparison
of SNOT-22 scores at 6 months by randomised treat-
ment arm (immediate surgery vs medical management).
Mean overall scores will be presented by treatment
group. The associated significance of any observed dif-
ference will be calculated in multivariable regression
models adjusting any treatment effect by stratification
factors, gender and NOSE severity at baseline. Secondary
analysis of the primary outcome measure will adjust for
the influence of baseline severity SNOT-22 score as a
continuous covariate, planned turbinate reduction as a
binary covariate and other important demographic and
clinical covariates at randomisation (including, but not
exclusively, age, body mass index (BMI), smoking, endo-
scopic features). Non-linear relationships between con-
tinuous baseline measures and outcome will be
addressed by simple, and possibly more complex, frac-
tional polynomial transformations.
The NAIROS model will generate a linear predictor
score of patient outcome weighted according to the stat-
istical importance of each covariate. Each patient’s linear
predictor score will be compared against observed score
for internal validation. This model will be used to ex-
plore recommendations for treatment options.
The importance of baseline severity, as a continuous dis-
tribution of NOSE score at randomisation, may be further
explored graphically by Subpopulation Treatment Effect
Pattern Plots (STEPP analysis) [40] to display the
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predicted point estimates of any treatment effect (with
95% CI) over the range of NOSE values (range 30–100 in
NAIROS participants), further informing any patient se-
lection guidance and recommendations.
Primary statistical analyses will be carried out on an
intention-to-treat basis. The number of ineligible partici-
pants and reasons for ineligibility will be reported. A sen-
sitivity analysis may be conducted and reported if the
number of ineligible participants or participants not re-
ceiving the allocated treatment is excessive. Participants
may choose to discontinue the treatment to which they
have been allocated, and may also ask that they receive an
alternative treatment as per local standard NHS care. The
implication of such treatment adjustments, which typifies
surgical trials, is that the intention-to-treat analysis will
produce a conservative estimate of the effect of septo-
plasty. Non-compliance (including receiving the alterna-
tive treatment) may be addressed using an ‘as treated’
approach or complier average causal effect (CACE) ap-
proach, since the intention-to-treat analysis under non-
compliance is biased when the intervention effect is large
[41]. Statistical methods for withdrawal of participants,
based on statistical censoring, may be considered.
Tests of heterogeneity will assess robustness of the over-
all treatment effect across stratification subgroups, and by
intention to perform unilateral turbinate reduction.
There are no formal interim analyses of the primary
outcome measure and there are no formal statistical
stopping rules. Decisions regarding continuation of the
trial will be made at DMC meetings held every 6
months. Decisions will be made on the basis of informa-
tion presented in a statistical report that includes ana-
lysis of formal data snapshots, including safety data.
Analysis of secondary outcomes Analyses of secondary
outcomes will follow a broadly similar strategy. These
will include the data at 6-month follow-up from the
other outcomes (SNOT-22 subscales, NOSE, DOASS,
SF-36) and that for all outcomes at 12-month follow-up.
Subjective scales, tabulated by arm and overall at ran-
domisation, 6-month and 12-month follow-ups, will be
compared by both summary statistics and graphical repre-
sentation. Multiple regression will be used to investigate
longitudinal outcome scores between treatment groups at
follow-up time points. Variation between participants will
be included as a random effect with an assumed normal
distribution. Analysis will include the stratification factors
of baseline severity and gender. Further adjusted analyses
will include terms for baseline values of the scores and key
demographic and clinical covariates.
Adverse events will be tabulated according to World
Health Organisation (WHO) Common Terminology Cri-
teria for Adverse Events (CTCAE) grade version 4.03.
Number of severe (CTC grade 3, 4 or 5) will be reported
as a proportion of all AEs. Number of participants ex-
periencing at least one severe CTCAE will be reported
as a proportion of all participants. Surgical complica-
tion/failure and re-intervention will be tabulated and will
not subject to statistical testing. Technical failures from
operations where widening of nasal airway was achieved
yet the symptoms persist will be reported.
Analysis of exploratory outcomes Three measure-
ments each of PNIF and NPR during maximal inhalation
will be made. Either the maximum (PNIF) or average
(NPR) value is used.
Summary statistics will be presented for PNIF and
NPR by arm and overall, at baseline, 6-month and 12-
month follow-ups.
Mixed-method process evaluation
Design The process evaluation incorporates the QRI
and mixed qualitative methods. Data collection and ana-
lysis will commence during study set-up and continue
throughout the trial.
Randomising patients between surgical and medical
arms can be challenging. The QRI, based at Bristol Uni-
versity, will assist in the identification and methods of
addressing such challenges. The QRI uses novel qualita-
tive and mixed-method approaches pioneered during the
National Institute for Health Research (NIHR) Health
Technology Assessment (HTA)-funded ProtecT (Pros-
tate testing for cancer and Treatment) study [42]. These
methods have since been applied to several other ‘chal-
lenging’ or controversial RCTs in different clinical con-
texts, all of which have led to insights about recruitment
issues and the development of generic and bespoke
strategies to optimise recruitment [43].
The QRI will coincide with the study set-up and the
first year of recruitment, using qualitative and novel
methods to investigate and address recruitment barriers
(objective A, below) [43–45]. Qualitative interviews will
be conducted throughout the trial to investigate patients’
and clinicians’ experiences of the study procedures, in-
terventions and barriers to implementing findings into
practice (objectives B and C, below).
Sampling strategy The sampling strategy is informed
by current and prior experience [42, 46, 47]. In keeping
with the principles of rigorous qualitative research, sam-
pling will be responsive to the study context. In some
cases fewer interviews or observations will be conducted,
and in others, additional data will be required to accom-
modate our emerging analysis or study events. Numbers
of interviews will be guided by ‘data saturation’ – contin-
ued sampling until findings become repetitious.
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Objective A: Optimising recruitment – QRI (study
set-up and first year of recruitment) Working in close
collaboration with the Trial Management Group (TMG),
the QRI team will assimilate investigational and inter-
ventional approaches to understand and address recruit-
ment difficulties in the early stages of NAIROS. The
findings and implications of the QRI will continue to be
implemented by the TMG and study investigators
throughout the remainder of the trial recruitment
period. The QRI will proceed in two iterative phases: a
detailed understanding of the recruitment process will
be developed in phase I, leading to tailored interventions
to improve recruitment in phase II.
Phase I: understanding the recruitment process and
how it operates in individual centres. A multi-faceted,
flexible approach will be adopted, comprising one or
more of the following methods:
(a) In-depth interviews, conducted with: members of
the TMG (n = 5–10); clinicians or researchers
involved in trial recruitment (n = 10–12); and
eligible patients who have been approached to
participate in the trial (n = 5–10). Interviews will
explore views on trial processes, perceptions of
equipoise, and information about how the protocol
is operationalised in clinical centres
(b) Audio-recording and non-participant observation of
consultations during which the trial is discussed
with patients, enabling identification of clear and
subtle obstacles to recruitment
(c) Mapping of eligibility and recruitment pathways –
noting the point at which patients receive
information about the trial, which members of the
clinical team they meet, and the timing and
frequency of appointments. The QRI researcher will
work closely with the clinical trials unit to compose
logs of potential RCT participants as they proceed
through screening and eligibility phases
(d) Regular observation of TMG and investigator
meetings to gain an overview of trial conduct and
overarching challenges (logistical issues, etc.)
(e) Scrutiny of study documentation (e.g. PISs) to
identify aspects that are unclear or potentially open
to misinterpretation
Phase 2: development and implementation of recruit-
ment strategies. Anonymised findings from Phase I will
be presented to the TMG, summarising the factors that
appear to be hindering recruitment. A plan of action will
be devised in collaboration with the TMG if there is
consensus that aspects of practice are amenable to
change. Interventions will be tailored to the nature of re-
cruitment challenges identified. Generic forms of inter-
vention may include ‘tips’ documents on how to explain
trial design and processes. Supportive feedback will be a
core component of the plan of action, with the exact na-
ture and timing of feedback dependent on the issues that
arise. Centre-specific feedback may cover institutional
barriers, whilst multicentre group feedback sessions may
address widespread challenges. Individual confidential
feedback will be offered where there is a need to discuss
specific challenges or potentially sensitive issues.
Objectives B and C: understanding experiences of
septoplasty and non-surgical management We will in-
vestigate patients’ (n = 16–20) and health professionals’
(n = 16–20) experiences of the interventions and trial
participation through qualitative interviews conducted
during patient follow-up. Where possible, patients for
the follow-up interviews will include those interviewed
during the recruitment phase; additional participants will
be recruited based on purposive and emergent criteria
(e.g. patients who have declined their allocated treat-
ment). We will identify any aspects of the care path-
way which are problematic for patients or health
professionals; and potential barriers and facilitators to
wider acceptance and implementation of trial findings.
A focus group of GPs will explore preliminary trial
findings and discuss implications for primary care
management of nasal obstruction. Our analysis of the
implementation of study findings will be informed by
Normalisation Process Theory (NPT) [48].
Qualitative data management and analysis All inter-
views will be audio-recorded, transcribed verbatim and
edited to ensure anonymity of respondents. Contempor-
aneous field notes from non-participant observation in
clinical settings will be edited to ensure anonymity of
participants. Data will be managed using NVivo soft-
ware. The analysis will be conducted according to the
standard procedures of rigorous qualitative analysis
which we have described previously [49], including open
and focussed coding, constant comparison [50], memo-
ing [50], deviant case analysis [51] and mapping [52].
We will undertake independent coding and cross-
checking and a proportion of data will be analysed col-
lectively in ‘data clinics’ where the research team share
and exchange interpretations of key issues emerging
from the data. Audio-recorded recruitment consulta-
tions will be subjected to content, thematic and novel
analytical approaches, including targeted conversation
analysis [52] and quanti-qual appointment timing (the
‘Q-Qat method’) [53]. There will be a focus on aspects
of information provision that is unclear, disrupted, or
potentially detrimental to recruitment and informed
consent.
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Post-trial care
All participants who complete the NAIROS trial, or who
discontinue the treatment interventions at any point, will
be offered standard, local NHS care in discussion with
their local investigator.
Indemnity
The sponsor will provide indemnity in the event that
trial participants suffer negligent harm due to the man-
agement of the trial. This indemnity will be provided
under the NHS indemnity arrangements for clinical neg-
ligence claims in the NHS.
Access to the final trial dataset
The Trial Steering Committee (TSC), Data Monitoring
Committee (DMC), trial statistician, data manager and
other members of the central trial team as required will
have access to the full trial dataset. Individual site trial
datasets will not be available to individual site investiga-
tors prior to publication of the main trial results. All re-
quests for data should be directed to the corresponding
author for consideration. Access to the anonymised final
trial dataset may be available following review; we will
retain exclusive use until publication of major outputs.
Dissemination of trial results
The results of the trial will be presented at topic-specific
national or international conferences and published in a
general medical journal with the monograph published
by HTA. Authorship of all publications will be on a
named individual authorship basis. For each publication,
all individuals who fulfil the authorship definition for the
publishing journal or site will be included as individually
named authors. Authorship order will be decided by the
chief investigator and TMG.
A lay summary of results and the HTA report will be
available on the NAIROS website. Members of the Pa-
tient and Public Involvement (PPI) panel will review re-
sults and they will be involved in writing lay summaries
of results for dissemination to relevant patient groups.
Trial monitoring
NCTU staff will monitor trial conduct and data integrity
to ensure that the trial is conducted in accordance to
the latest directive on GCP (2005/28/EC). This will be
detailed in a Data Management Plan and a Monitoring
Plan approved by the trial sponsor.
Safety reporting Delegated nursing staff will interview
participants to collect and record any AEs. This will take
place at every trial visit (n = 3), and also via safety phone
calls; 2 weeks after randomisation for medical manage-
ment arm participants, and 2 weeks after septoplasty for
surgical arm participants.
Serious adverse events (SAEs) will be assessed for any
relationship to the treatment intervention (causality), and
expectedness (by reference to the Reference Safety Infor-
mation (RSI)) of any serious adverse reactions (SARs).
Only a qualified medical doctor, delegated to do so at site,
may assess the causality and expectedness of each SAE.
Trial Management Group A Trial Management Group,
facilitated by NCTU, will convene approximately
monthly throughout the duration of the trial. Members
will consist of key NCTU staff, the chief investigator,
local clinical co-applicants, trial statisticians, a sponsor
representative and staff representing Health Economics,
Qualitative and QuinteT recruitment intervention teams.
Independent Data Monitoring Committee An inde-
pendent Data Monitoring Committee (DMC) has been
appointed to provide an independent review of partici-
pant safety and data endpoints. The independent mem-
bers comprise two statisticians and a clinician.
The DMC will meet at least annually, and report dir-
ectly to the Trial Steering Committee (TSC).
Trial Steering Committee A TSC has been appointed
to provide overall independent supervision of the trial.
Members consist of an independent chair, two inde-
pendent clinicians, an independent statistician, an inde-
pendent health economist and three patient
representatives. The TSC will meet least annually, after a
DMC meeting.
Key changes to protocol
All substantial changes to the protocol were approved by
the local UK HRA Research Ethics Committee, and stan-
dalone minor changes (version 4.1) were approved by
the Health Research Authority (HRA), prior to imple-
mentation at sites. The current, full protocol is available
to view on the trial funder’s website: https://fundinga-
wards.nihr.ac.uk/search. A summary of key changes to
the protocol during the trial is listed in Table 2.
Discussion
There is a paucity of evidence underlying the indications
for septoplasty in the UK. At present, the decision to
perform septoplasty is based on the clinician’s subjective
estimation of the impact on the affected nasal airway
caused by a deviated septum. In addition, there is a lack
of evidence of the impact of a standardised topical med-
ical treatment regimen on the nasal airway in the pres-
ence of a septal deflection.
At a time of rising healthcare costs and increasing
scrutiny on the requirement to justify clinical interven-
tions there is an urgent need to answer these questions.
The aim of NAIROS is to perform a RCT to compare
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surgical treatment to a standardised dual medical therapy
(Sterimar spray and mometasone spray) and estimate the
effectiveness based on subjective nasal symptoms, object-
ive airway measurements and the impact on quality of life.
Furthermore, a number of other interactions will be mea-
sured at baseline, 6 and 12months following randomisa-
tion. The impact of known covariates including sex,
turbinate enlargement and subjective degree of nasal ob-
struction will be assessed.
NAIROS is a pragmatic ‘real-world’ trial, researching a
common surgical intervention against a contemporary
comparator in such a way that the results will be gener-
alisable to NHS patients in whom it is offered. However,
limitations are anticipated in both treatment arms. In
the surgical arm clinicians may vary in their assess-
ment and documentation of the nasal septum deflec-
tion. It is also recognised that there are shortcomings
in objective measurements of the nasal airway [54]. In
the medical arm we are not monitoring quantities of
nasal-steroid used and instead relying on patient-
reported use.
NAIROS will also compare the cost-effectiveness, to
the patient and the NHS, of both the medical and surgi-
cal arms of the trial. The challenges and barriers to pa-
tient recruitment will be analysed by the Quintet
Recruitment Intervention with a view to identifying and
minimising these. A qualitative evaluation will explore
the views of participants and staff and their experience
of the intervention to enable us to shape guidelines and
inform clinical decision-making in patients with a devi-
ated nasal septum. The overarching aim will be to shape
future guidance on the management of a deviated nasal
septum in an NHS setting.
Trial status
The NAIROS trial is currently working to protocol ver-
sion 5.0, dated 16 January 2019. Recruitment began on
18 January 2018, and is due to end on 31 January 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4081-1.
Additional file 1. Patient Information Sheet, V5.1 dated 27 March 2019.
Additional file 2. Nasal Airway Obstruction Study (NAIROS) Main
Informed Consent Form, V3.0 dated 16 Jan 2019.
Additional file 3. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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